SEC Form 4 · accession 0001562180-18-000238
REGENXBIO Inc. · RGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth T. Mills
Officer — President and CEO · Director
Period of report
Jan 3, 2018
Accepted (ET)
Jan 5, 2018 · 4:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590877
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $35.80 | Jan 3, 2018 | A | 163,500 | A | — | Jan 3, 2028 | Common Stock | 163,500 | 163,500 | D |
Explanation of responses
- F125% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2019 while the optionee provides continuous service to the Issuer.
Remarks
EXHIBIT LIST - Exhibit 24 - Power of Attorney for Kenneth T. Mills